NeoProspect HER2-low: Response and Prognosis After Neoadjuvant Treatment in Patients with HER2-low Breast Cancer.

Cureus · 2026 · PMC12967737 · PMID 41804394

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

20% in HER2-low), although this difference did not reach statistical significance in our exploratory analysis.

also in 111,027 other papers

a numerical trendno p-value reported

2+) did not identify statistically significant differences in pCR or RCB class, but we observed a numerical trend toward higher pCR and lower RCB in HER2 1+ compared with HER2 2+ tumours.

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.